论文部分内容阅读
目的 研究鼻腔癌 (NPC)高发的广州地区鼻腔鼻窦淋巴上皮性癌 (SNLEC)的发病情况 ,并检测其是否感染EB病毒 (EBV)。方法 从广州地区 8年内所有鼻腔鼻窦癌的活检标本中 ,收集其中确定为淋巴上皮性癌的标本 2 0例。用原位杂交法检测EBV编码的早期RNAs ,同时用免疫组化法检测各种不同的抗原 ,包括EBV核抗原 1、潜伏膜蛋白 1、EZLF1蛋白、弥漫型早期抗原、病毒壳抗原和膜抗原。此外 ,另取 36例鼻咽癌作为对照。结果 在确诊的 2 0例SNLEC中 ,17例在鼻腔 ,3例在上颌窦。 2 0例SNLEC患者的平均年龄 (46 2 5岁 )、男女比例(3∶1)、组织病理学和淋巴细胞浸润的情况与 36例鼻咽癌者类同。 2 0例SNLEC中的 13例 (6 5 0 % )呈膨胀型生长方式 ,而 36例NPC中的 2 7例 (75 0 % )则呈浸润型生长方式。所有 2 0例SNLEC中的绝大多数癌细胞均显示EBV编码的早期RNAs。SNLEC和EBV核抗原 1的表达强度比鼻咽癌弱 ,SNLEC的潜伏膜蛋白 1的表达率 (3/ 2 0 ,15 0 % )低于鼻咽癌患者 (19/ 36 ,52 8% )。SNLEC的BZLF1蛋白 (2 / 2 0 ,10 0 % )、弥漫型早期抗原 (19/ 2 0 ,95 0 % )、病毒壳抗原 (15/ 2 0 ,75 0 % )和膜蛋白 (13/ 2 0 ,6 5 0 % )的表达率均高于NPC者 (0 / 36 ,0 0 % ;31/ 36 ,86 0 % ;18/ 36 ,50 %和 14/ 36 ,38
Objective To study the incidence of nasal sinusoidal epithelial carcinoma (SNLEC) in Guangzhou with high incidence of nasal cancer (NPC) and detect whether it is infected with Epstein-Barr virus (EBV). Methods Twenty cases of nasal sinus cancer were collected from all samples of nasal sinus cancer within 8 years in Guangzhou. EBV-encoded early RNAs were detected by in situ hybridization and various antigens were detected by immunohistochemistry including EBV nuclear antigen 1, latent membrane protein 1, EZLF1 protein, diffuse early antigen, virion antigen and membrane antigen . In addition, another 36 cases of nasopharyngeal carcinoma as a control. Results Of the 20 confirmed SNLECs, 17 were in the nasal cavity and 3 were in the maxillary sinus. The mean age (46 2 5 years), male to female ratio (3:1), histopathology and lymphocyte infiltration in 20 SNLEC patients were the same as those in 36 cases of NPC. Thirteen (65.0%) of 20 SNLECs showed an intumescent growth pattern, while 27 of 75 (75%) of 36 NPCs showed an invasive growth pattern. The vast majority of cancer cells in all 20 SNLECs showed EBV-encoded early RNAs. The expression of SNLEC and EBV nuclear antigen 1 was weaker than that of NPC. The expression of latent membrane protein 1 (SNP) of SNLEC was lower than that of NPC (3/36, 52.8%). The SNPs of BZLF1 protein (20/100, 100%), diffuse early antigen (19/200, 95%), viral shell antigen (15/200, 75%) and membrane protein (0/36, 0 0%; 31/36, 86 0%; 18/36, 50%, 14/36, 38%, respectively)